Butabarbital decreases effects of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of CYP3A4 inducers may well minimize sufentanil degrees and efficacy, possibly precipitating withdrawal syndrome in patients who have designed physical dependence to sufentanil. Discontinuation of concomitantly employed CYP3A4 inducer... https://franceso580kzn9.izrablog.com/profile